~~<i id='F829378EE8'><strike id='F829378EE8'><tt id='F829378EE8'><pre id='F829378EE8'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：entertainment 2025-09-06 05:56:15 Page View：933

AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Listen: Biogen's situation, Wegovy's risks, & biotech insider trading
Next article： State Dept. review finds Biden bears some blame for Afghanistan failures

knowledge

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

FILE-Alineof2022SantaFeSUV'ssitoutsideaHyundaidealershipSunday,Sept.12,2021,inLittleton,Colo.Indocum

Sports medicine is finally prioritizing gender equality

MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

Texas board proposes rules on abortion law emergency exemption

MishaFriedman/GettyImagesTheTexasMedicalBoard,respondingtopressurefromthestateSupremeCourtandwidespr